Percutaneous microwave coagulation therapy under contras-enhanced grey-scale ultrasonography guidance combined with TACE for the treatment of hepatic metastatic carcinomas

Wei XU,Yu-ming GU,Xing-tian WANG,Hao XU,Jiao LU,Mao-heng ZU,Qing-qiao ZHANG,Yong WANG,Hao-guang WAN
DOI: https://doi.org/10.3969/j.issn.1008-794X.2012.10.006
2012-01-01
Abstract:Objective: To evaluate the clinical efficacy of percutaneous microwave coagulation therapy (PMCT) under contrast-enhanced grey-scale ultrasonography (CEUS) guidance combined with transcatheter arterial chemoembolization (TACE) in treating hepatic metastatic carcinomas. Methods: Fifty patients with clinically conformed hepatic metastatic carcinomas were randomly and equally divided into two groups: the combination group and the control group. Patients in the combination group (n = 25) received TACE together with PMCT treatment, while patients in the control group (n = 25) were treated with TACE alone. The therapeutic results were analyzed and compared between the two groups. Results: In the combination group, complete remission (CR) was seen in 7 cases, partial remission (PR) in 15 cases, stable disease (SD) in 2 cases and progressive disease (PD) in one case, with a remission rate of 88%. In the control group, CR was seen in 3 cases, PR in 11 cases, SD in 6 cases and PD in 5 cases, with a remission rate of 56%. The difference in the remission rate between the two groups was statistically significant (P < 0.05). In the combination group, the levels of T cell subsets (CD3, CD4, CD 16CD56 and CD3CD56) determined after the treatment were significantly higher than those determined before the treatment (P < 0.05). Conclusion: For the treatment of hepatic metastatic carcinomas, CEUS-guided PMCT combined with TACE s superior to pure TACE. The clinical efficacy can be significantly improved.
What problem does this paper attempt to address?